Alterity Therapeutics Limited

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of lead pipeline asset plus net cash, since this is a pre-revenue clinical-stage biotech: $2.4B independently-assessed global peak sales estimate for ATH434 in multiple system atrophy; assumed 15% royalty/commercial economics to Alterity at an 85% margin ($306M peak annual risked-off cash flow); 20% probability of success from completed Phase 2 to approval (orphan/fast-track designations, positive Phase 2 data, pre-Phase 3); 4-year ramp to peak beginning in year 5 (post Phase 3 and approval), peak sustained years 8-12, no terminal value assumed after exclusivity; 12% discount rate; $25.68M net cash added unrisked; approximately 17.47 million ADS shares outstanding (implied by $66.05M market cap / $3.78 ADS price).

Reasoning: Alterity has no revenue and negative operating cash flow, so a standard FCF DCF is not applicable; a probability-weighted NPV of its single clinical-stage asset (ATH434, post-Phase-2 in a rare neurodegenerative disease) plus its cash balance is the standard biotech-appropriate method, and the low probability of success reflects that Phase 3 has not yet begun and clinical attrition risk remains high.